Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
SUMMARY: Introduction:Central neurochemical systems including the monoamine, opioid, and cannabinoid systems have been promising targets for antiobesity drugs that modify behavioral components of obesity. In addition to modulating eating behavior, centrally acting antiobesity drugs are also likely to alter emotional behavior and cognitive function due to the high expression of receptors for the neurochemical systems targeted by these drugs within the fronto‐striatal and limbic circuitry.Methods:This paper reviewed the neuropsychiatric adverse effects of past and current antiobesity drugs, with a central mechanism of action, linking the adverse effects to their underlying neural substrates and neurochemistry.Results:Antiobesity drugs were found to have varying neuropsychiatric adverse event profiles. Insomnia was the most common adverse effect with drugs targeting monoamine systems (sibutramine, bupropion and tesofensine). These drugs had some positive effects on mood and anxiety and may have added therapeutic benefits in obese patients with comorbid depression and anxiety symptoms. Sedation and tiredness were the most common adverse effects reported with drugs targeting the m‐opioid receptors (i.e., naltrexone) and combination therapies targeting the opioid and monoamine systems (i.e., Contrave™). Cognitive impairments were most frequently associated with the antiepileptic drugs, topiramate and zonisamide, consistent with their sedative properties. Drugs targeting the cannabinoid system (rimonabant and taranabant) were consistently associated with symptoms of anxiety and depression, including reports of suicidal ideation. Similar adverse events have also been noted for the D 1/D 5 antagonist ecopipam.Conclusion:These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“The expression of CB1 receptors is particularly high within areas of the brain associated with regulation of emotion, including the prefrontal cortex, hippocampus, amygdala, and periaqueductal gray [100,103], suggesting that drugs modulating the CB1 receptor may induce anxiety or depressive like behaviors.”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“, fear extinction) [108].”
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“The cannabinoid type 1 (CB1) receptors are widely distributed in the central nervous system, located mainly in presynaptic terminals of neurons [100] and in particular, on GABAergic interneurons expressing the α2 subunit enriched GABAA receptors [101,102].”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“5 and 3 times more likely to discontinue treatment because of depressive or anxiety symptoms respectively [124].”
BackgroundPsychological correlates of obesity: Moving to the next research generation.
Friedman, M. A., & Brownell, K. D. (1995) · Psychological Bulletin · doi:10.1037/0033-2909.117.1.3 · Cited by 863
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 2×
“The cannabinoid type 1 (CB1) receptors are widely distributed in the central nervous system, located mainly in presynaptic terminals of neurons [100] and in particular, on GABAergic interneurons expressing the α2 subunit enriched GABAA receptors [101,102].”
BackgroundSvanborg, P., & Åsberg, M. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01480.x · Cited by 693 · cited 1×
“For example, an open labeled study of sibutramine (15 mg) in obese patients showed a reduction in depression scores (assessed using the comprehensive psychopathological rating scale, [21]) over 6 months of treatment [22].”
BackgroundMice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672
Cited by
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
The link between stress and feeding behaviour
Maniam, J., & Morris, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.017 · Cited by 255
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
“A cannabinoid receptor type 1 (CB1R) antagonist, rimonabant, that was approved by the European Medicines Agency (EMEA), but not by the Food and Drug Administration (FDA) was withdrawn in 2009 due to concerns about increased risk of suicidal ideation [7].”
Metadata
- Authors
- Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2011-09-23
- Volume
- 17
- Issue
- 5
- Pages
- 490-505
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1543336396
- Cited by
- 113
- References
- 29
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00172.x
- The paper
- Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2011). Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00172.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.